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(2.3%, 10.9% and 14.3%, respectively, p b 0.01). Other clinical character-
istics associated with new-onset AF were different in STEMI and
NSTEMI (Table 1). In STEMI, LV systolic dysfunction, coronary anatomy,
peak troponin and invasive treatment were not associated with new-
onset AF. On the other hand, in NSTEMI revascularization procedures
[percutaneous coronary intervention (PCI) or thrombolysis] reduced
the risk of new-onset AF (5.6% vs 11.2%, p b 0.01). Peak troponin level
was also marginally associated with AF in NSTEMI (from 8.4% in the
ﬁrst quartile of troponin I to 14.2% in the fourth, p = 0.09). AmongAtrialﬁbrillation (AF) is a common complication of acutemyocardial
infarction (AMI) associatedwith increasedmortality [1]; however new-
onset AF is less well characterized according to the type of AMI. We
sought to study the incidence, predictors and prognosis of new-onset
AF complicating ST-segment elevation AMI (STEMI) and non-ST-
segment elevation AMI (NSTEMI).
Data was derived from the Portuguese sample of EURHOBOP
(European Hospital Benchmarking by Outcomes in acute coronary syn-
drome Processes), a multicenter retrospective study of patients hospi-
talized with an acute coronary syndrome (ACS). The discharge notes
and medical ﬁles were retrospectively reviewed by trained data extrac-
tors. A patient was considered to have new AF if the arrhythmia ap-
peared at any time during hospitalization. Patients with previous
diagnosis of AF described in medical records were excluded. The ﬁnal
sample included 977 episodes of STEMI and 1357 of NSTEMI. This
study was approved by the ethics committee of Hospital de São João
and the National Commission for Data Protection.
The cumulative incidence of new-onset AF during the hospitaliza-
tion was 8.9% and there was no difference according to the type of
AMI (STEMI and NSTEMI) (8.8% vs 9.0%, p = 0.87; respectively).demiology, Predictive Medicine
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.The incidence of AF increased with age in both STEMI (b60 years:
3.1%; ≥60 b 80 years: 11.8%; ≥80 years: 17.0%, p b 0.01) and NSTEMI
NSTEMI patients who underwent coronary angiography, increasing se-
verity of coronary anatomy increased the risk of new-onset AF (1-, 2-
and 3-vessel disease: 4.1%, 6.0%, and 8.2%, respectively, p = 0.14)
(Table 1).
Inmultivariate analysis (Table 2), advanced agewas an independent
predictor of new-onset AF in STEMI (OR 4.20; 95% CI 2.11–8.37 and OR
6.73; 95% CI 2.94–15.40 for 60–79 years and ≥80 years, respectively)
and NSTEMI (OR 5.24; 95% CI 2.47–11.11 and OR 6.25; 95% CI 2.74–
14.26 for 60–79 years and ≥80 years, respectively). Revascularization
procedures reduced the risk of new-onset AF in NSTEMI by a half
(age-, sex-, peak troponin- and LV-systolic-function-adjusted OR 0.46;
95% CI 0.28–0.78) and peak troponin I level N37.00 ng/mLwas associat-
ed with new-onset AF in NSTEMI (age, sex, treatment- and LVSD-
adjusted OR 1.96; 95% CI 1.02–3.75). Sex and LV systolic function were
not independent predictors of new-onset AF in either STEMI or NSTEMI.
In the total sample 459 cases of HF (19.1% in STEMI and 20% in
NSTEMI groups) and 154 deaths were registered (9.5% in STEMI and
4.5% in NSTEMI). New-onset AF was associated with a higher risk of
the composite endpoint of clinical HF or death (43.3% vs 22.0%,
p b 0.01). This association was signiﬁcant, when adjusting for age, sex,
LV systolic function and revascularization in both STEMI (OR 2.89; 95%
CI 1.75–4.80) and NSTEMI (OR 1.69; 95% CI 1.11–2.58) patients (p for
interaction = 0.18).
The major study that examined the occurrence of new-onset AF ac-
cording to the AMI presentation type showed that AF was associated
with older age, female sex, higher admission heart rate and hyperten-
sion history, in the STEMI and NSTEMI groups [2]. It did not analyze
the relation between new-onset AF and LV systolic dysfunction,
Table 1
Incidence of new-onset atrial ﬁbrillation according to demographic and clinical characteristics.
Type of AMI
Total sample STEMI NSTEMI
Incidence of AF, n (%) p Incidence of AF, n (%) p Incidence of AF, n (%) p
Age (years), n (%) b0.01 b0.01 b0.01
b60 22 (2.7) 13 (3.1) 9 (2.3)
60–79 128 (11.2) 50 (11.8) 78 (10.9)
≥80 58 (15.3) 23 (17) 35 (14.3)
Sex, n (%) 0.02 0.49 0.016
Female 80 (10.9) 24 (9.9) 56 (11.5)
Male 128 (8.0) 62 (8.4) 66 (7.6)
Peak troponin I (ng/mL), n (%)a 0.16 0.50 0.09
b2.84 43 (8.4) 8 (8.6) 35 (8.4)
2.84–11.00 37 (7.2) 8 (6.4) 29 (7.5)
11.01–37.00 49 (9.6) 18 (7.6) 31 (11.3)
N37.00 57 (11.2) 40 (10.3) 17 (14.2)
Peak troponin T (ng/mL), n (%)b 0.32 0.51 0.87
b0.57 3 (4.9) 0 3 (5.8)
0.57–1.78 4 (6.6) 1 (5.6) 3 (7.0)
1.79–4.32 4 (6.6) 3 (10.0) 1 (3.2)
N4.32 8 (13.3) 7 (14.3) 1 (9.1)
Coronary anatomyc, n (%) 0.33 0.70 0.14
1-vessel disease 42 (6.0) 30 (7.3) 12 (4.1)
2-vessels disease 34 (7.4) 19 (9.2) 15 (6.0)
3-vessels disease 31 (8.3) 11 (8.5) 20 (8.2)
Treatment, n (%) b0.01 0.08 b0.01
Invasived 88 (6.9) 58 (7.9) 30 (5.6)
Conservative 120 (11.3) 28 (11.6) 92 (11.2)
LV systolic function b0.01 0.22 0.01
Normal (EF ≥ 40%) 123 (8.5) 53 (8.8) 70 (8.3)
Abnormal (EF b 40%) 52 (12.7) 22 (11.2) 30 (14.1)
Unknown 33 (6.8) 11 (6.1) 22 (7.2)
Totals may differ due to missing data.
AF: atrial ﬁbrillation; AMI: acute myocardial infarction; EF: ejection fraction; LV: left ventricle; NSTEMI: non-ST-segment elevation acute myocardial infarction; STEMI: ST-segment
elevation acute myocardial infarction.
a Troponin I applies to 2088 patients from 9 hospitals.
b Troponin T applies to 246 from 1 hospital.
c Among patients who underwent coronary angiography.
d STEMI: invasive treatment comprises thrombolysis, PCI and/or CABG; NSTEMI: invasive treatment comprises PCI and/or CABG.
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vative). Also the association between the severity of AMI presentation
and AF incidence is not consistent. While some studies clearly showed
that AF was more common in STEMI than in NSTEMI [3,4], in others
AF occurred in similar frequency regardless of AMI type [5] or was
even higher in NSTEMI [6]. In our study STEMI vs NSTEMI nature of
myocardial damage did not inﬂuence the propensity to develop in-
hospital AF.
AF occurrence during AMI may reﬂect the inﬂuence of myocardial
ischemia, leading to left ventricular failure or signiﬁcant diastolic left
ventricular dysfunction, and consequently increasing atrial stretch [7].
P-wave duration and dispersion observed in patients with AMI and AF
were abolished after reperfusion with either thrombolysis or primary
PCI [8], reinforcing the role of ischemia in arrhythmia development.
These observations are consistentwith angiographic ﬁndings of a signif-
icantly higher proportion of patients with new-onset AF having more
severe multivessel or left main coronary artery disease [4]. In our
NSTEMI group, increasing severity of coronary anatomy increased the
new-onset AF incidence and revascularization procedures reduced the
risk of AF by almost half.We interpret this ﬁnding as evidence thatmyo-
cardial ischemia contributes to AF in NSTEMI patients. We hypothesize
that the same pattern was not observed in STEMI patients because
these are more often revascularized, as occurred in our study (invasive
treatment in 75% of STEMI and 40% of NSTEMI population).
AF is commonly considered an independent marker of poor progno-
sis. Virtually all studies have reported that patients with AF after AMI
experienced higher short- and long-term mortality rates [1,2,9,10].Our ﬁndings were consistentwith poorer in-hospital outcomes (clinical
heart failure or death) during hospitalization, regardless of AMI type
(STEMI vs NSTEMI).
Certain limitations of our study must be acknowledged. First this
was a retrospective analysis, having the limitations inherent to such a
study design. Second, patients who had prior AF were excluded, but
some cases not reported in clinical records may have been classiﬁed as
having AF as an AMI complication. Finally, timing of AF in relation to
coronary reperfusion was not recorded.
In conclusion, new-onset AF was common in patients hospitalized
with AMI with an identical incidence between STEMI and NSTEMI. Old
age was the strongest predictor of the development of new-onset AF
in AMI. In NSTEMI myocardial ischemia may be contributing to new-
onset AF. New-onset AF was associated with a 2-to-3-fold increase in
death or heart failure. The signiﬁcant impact of new-onset AF in AMI
warrants attention towards this arrhythmia and reinforces the instiga-
tion for an aggressive approach to avoid myocardial ischemia.
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Table 2
Predictors of new-onset atrial ﬁbrillation.
Type of AMI
STEMI
n = 845
NSTEMI
n = 1198
OR (95% CI)a OR (95% CI)a
Age (years)
b60 1 1
60–79 4.20 (2.11–8.37) 5.24 (2.47–11.11)
≥80 6.73 (2.94–15.40) 6.25 (2.74–14.26)
Sex
Male 1 1
Female 0.86 (0.48–1.52) 1.23 (0.81–1.87)
Peak troponin I (ng/mL), n (%)
b2.84 1 1
2.84–11.00 0.88 (0.31–2.49) 0.77 (0.45–1.29)
11.01–37.00 0.98 (0.40–2.40) 1.37 (0.80–2.32)
N37.00 1.39 (0.61–3.18) 1.96 (1.02–3.75)
Treatment
Conservative 1 1
Invasiveb 0.61 (0.35–1.07) 0.46 (0.28–0.78)
LV systolic function
Normal (EF ≥ 40%) 1 1
Abnormal (EF b 40%) 0.75 (0.38–1.46) 1.22 (0.72–2.06)
Unknown 0.51 (0.24–1.06) 0.62 (0.36–1.04)
AF: atrial ﬁbrillation; AMI: acute myocardial infarction; EF: ejection fraction; LV: left
ventricle; NSTEMI: non-ST-segment elevation acute myocardial infarction; STEMI: ST-
segment elevation acute myocardial infarction.
a Odds ratio adjusted for all variables in the table. Only patients with complete data on
all these variables, and from the 9 hospitals where troponin I is used were included.
b STEMI: invasive treatment comprises thrombolysis, PCI and/or CABG; NSTEMI: inva-
sive treatment comprises PCI and/or CABG.
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